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INTRODUCTION
Malaria still remains as a problem for a high proportion of 
population in the world. The infection is responsible for about 
1-2 million deaths per annum [1] and more than 40% of the 
population are living in areas where malaria is endemic [2]. It 
was estimated that nearly 1 billion people are exposed to ma-
laria in hypoendemic and mesoendemic areas in southeast 
Asia [3]. Although Plasmodium falciparum shows a high mortal-
ity rate, Plasmodium vivax malaria has a wider geographical dis-
tribution and represents the most widespread malaria parasite 
worldwide. P. vivax is responsible for approximately 80 mil-
lion malaria-infected cases annually [4]. In Iran, P. vivax is re-
sponsible for more than 80% of the infected cases per year. In 
recent years, Iran has been engaged with malaria control pro-
grams. With these efforts, the total malaria reported cases in 
Iran from 96,340 with about 55% P. vivax in 1991 decreased 
to 18,966 with 88% P. vivax in 2005, and during these years P. 
vivax has been highly prevalent in the country [5]. Contempo-
raneous population movement of Afghani and Pakistani refu-
gees from endemic areas toward to the south and southeast of 
Iran changes the numbers of population living in the areas of 
malaria risk. So, we need new information about endemicity 
of malaria in areas where malaria has been endemic.
It is therefore important to recognize and assess the potenti-
ality of immunodominant P. vivax diagnostic antigens. This 
idea implies that the proteins bear such capacity to sensitize 
the immune system to produce specific antibodies [6,7]. The 
specific antibodies to the blood stages can be detected and rise 
to high levels during couple of days following clinical signs 
that are simultaneous to the emergence of parasites in the pa-
tient’s blood and remain for months and rarely years, and then 
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Abstract: In Iran, Plasmodium vivax is responsible for more than 80% of the infected cases of malaria per year. Control 
interventions for vivax malaria in humans rely mainly on developed diagnostic methods. Recombinant P. vivax apical mem­
brane antigen­1 (rPvAMA­1) has been reported to achieve designing rapid, sensitive, and specific molecular diagnosis. 
This study aimed to perform isolation and expression of a rPvAMA­1, derived from Iranian patients residing in an endemic 
area. Then, the diagnostic efficiency of the characterized Iranian PvAMA­1 was assessed using an indirect ELISA method. 
For this purpose, a partial region of AMA­1 gene was amplified, cloned, and expressed in pET32a plasmid. The recombi­
nant His-tagged protein was purified and used to coat the ELISA plate. Antibody detection was assessed by indirect ELI­
SA using rPvAMA­1. The validity of the ELISA method for detection of anti­P. vivax antibodies in the field was compared 
to light microscopy on 84 confirmed P. vivax patients and compared to 84 non­P. vivax infected individuals. The ELISA 
cut­off value was calculated as the mean+2SD of OD values of the people living in malaria endemic areas from a south 
part of Iran. We found a cut­off point of OD=0.311 that showed the best correlation between the sera confirmed with P. 
vivax infection and healthy control sera. A sensitivity of 81.0% and specificity of 84.5% were found at this cut off titer. A 
good degree of statistical agreement was found between ELISA using rPvAMA­1 and light microscopy (0.827) by Kappa 
analysis. 
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decline to inactive levels [8]. Assessment of these antibodies in 
serological studies are generally recognized valuable to supple-
ment parasitological data as well as transmission and immu-
nity of malaria [9]. Apical membrane antigen-1 (AMA-1) is a 
micronemal protein of apicomplexan parasites to be found on 
the apical organelles of merozoites that performs significant 
roles during the attack of host cells. After natural infection, Pv-
AMA-1 stimulates immune responses, and the produced anti-
bodies can have profound parasite-inhibitory effects and can be 
detected in human sera by using an appropriate antigen [10]. 
In general, malarial parasite antigens could be obtained from 
parasite cultivation [11], but P. vivax is particularly considered 
as a non-cultivable parasite. In earlier studies, ELISA and indi-
rect fluorescence methods were used to measure antibody as-
sessment for epidemiological studies of malaria, and the anti-
gens for established ELISA tests were achieved from Aotus mon-
key. Therefore, in this study, we performed isolation and ex-
pression of a rPvAMA-1, derived from Iranian patients residing 
in an endemic area. Then, the diagnostic efficiency of the char-
acterized Iranian PvAMA-1 was assessed using an ELISA method. 
MATERIALS AND METHODS
Study area
The sera were collected from malaria endemic areas of Iran. 
These parts are located in the south-east of the country, bor-
dered in the north coast of the Persian Gulf and Oman Sea 
and to the east by Pakistan and Afghanistan. These parts in-
clude the provinces of Hormozgan and Sistan & Baluchestan. 
Hormozgan has hot and humid weather in most months of 
the year, and the annual average rainfall was calculated as 196 
mm. Sistan & Baluchestan has hot and dry weather for 9 mon-
ths and the annual average rainfall was calculated as 65 mm.
Serum collection and microscopic examinations 
A total of 168 serum samples were collected for serological 
analysis by venipuncture of patients. Total 84 serum samples 
were obtained from patients who were resident in malaria en-
demic regions in Iran with symptomatic P. vivax malaria con-
firmed by detecting parasites in thick and thin blood films us-
ing Giemsa stain. Negative controls, including 79 samples were 
from healthy individuals as well as 9 samples from patients 
infected with Toxoplasma, Leishmania infantum, and FUO (fever 
of unknown origin) who had never exposed to malaria, and 
finally 3 sera from infected patients with P. falciparum. More-
over, 60 normal sera were collected to define a cut off value; 
these subjects were residents in malaria endemic areas but in 
healthy situation. Serum samples were collected after receiving 
informed consent by all individuals during the period from 
2009 to September 2010. The sera were frozen at -70˚C until 
used. 
Preparation of rPvAMA­1 antigen
Parasite DNA extraction
The genomic DNA was purified from the infected erythro-
cytes of a patient with vivax malaria, using Genomic DNA Ex-
traction Kit, ACCUPreP® kit (BIONEER, Incheon, Korea) ac-
cording to the manufacturer’s instructions. The extracted DNA 
was checked by biophotometer and used as the template for 
PCR with primers corresponding to the AMA-1 region as will 
be mentioned below. 
Cloning and expression of PvAMA-1 in Escherichia coli
The nucleotide sequence corresponding to amino acid (AA) 
residues 43-487 of PvAMA-1, involving the internal regions 
(domain I, domain II and domain III) of the PvAMA-1 gene, 
was obtained by PCR amplification using the following set of 
primers PvAMAF 5´-CCATGGGGCCTACCGTTGAGAGAA-3´ 
and PvAMAR 5´-CTCGAGTCATAGTAGCATCTGCTTGTT-3´. This 
pair of primers was designed regarding the P. vivax Sal-1 AMA-
1 (GenBank ID: XM_001615397). These primers contained re-
striction enzyme sites for cloning and expression in the pro-
karyotic host. PCR was performed as same as described else-
where (Motevalli et al. in press). The PCR product was purified 
from an agarose gel using Qiaquick GEL Extraction kit (QIA-
GEN, Hilden, Germany) and cloned in pUC19 cloning vector 
using Rapid DNA ligation kit (Roche, Mannheim, Germany). 
The resulted recombinant plasmid was transform  ed into E. coli 
Novablue by heat shock. The transformants were plated on LB 
agar medium, containing ampicillin (100 µg/ml), IPTG (1 mM), 
and X-gal (50 µg/ml) for blue-white selection. A single white 
colony was picked and cultured in LB medium with ampicillin 
(100 µg/ml) at 37˚C with shaking (160 rpm) for 3 hr, and veri-
fication of cloning was carried out by PCR. Then, the recombi-
nant pUC19 plasmid was purified by the High pure plasmid 
purification kit (Roche) and was cut by NcoI and XhoI to sub-
clone in the pET32a as a bacterial expression vector. The re-
combinant pET32a-AMA-1 was transformed into E. coli Nov-
ablue as described previously, then it was purified and sent for 
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host cells was then carried out using a purified and verified re-
combinant plasmid. A single positive clone was considered for 
AMA-1 expression, it was cultured in LB medium containing 
100 µg/ml ampicillin at 37˚C with shaking for 3 hr to reach 
OD 0.4, then 1 mM of IPTG as a gene expression inducer was 
added to the culture and the culture was continued for another 
3 hr. After incubation, the culture was centrifuged and the cell 
mass resuspended in sonication buffer (50 mM Tris-HCl, pH 
8.0, 100 mM NaCl, 1 mM EDTA, 50 mM phenylmethylsulfo-
nyl floride [PMSF] and 80 mg/ml of lysozyme) and was lysed 
during 6 sonication cycles consisting of 10 sec burst at high in-
tensity and 10 sec cooling period on ice. Then, the bacterial ly-
sate was centrifuged at 6,500 g for 30 min at 4˚C to remove 
bacterial debris, and the supernatant was applied to confirm 
the expression by SDS-PAGE. Gel was stained with coomassie 
blue.
Purification of rPvAMA-1
The recombinant His-tagged protein was purified from the 
supernatant of the bacterial lysate by Nickel-Chelating Resin 
column using the ProBond purification system kit (Invitrogen, 
Carlsbad, California, USA) in native conditions according to 
the ma  nufacturer’s protocol. The resulting protein was ana-
lyzed on 12% SDS-PAGE, calculated by Bradford assay (Bio-
Rad, Hercules, California, USA) and used for ELISA. 
Design and assessment of an indirect ELISA method by 
using rPvAMA­1
Antigen coating and optimization and test sera dilutions
A checkerboard ELISA was performed to determine the work-
ing concentrations of the coating antigen and antibody to as-
sess present malaria antibodies in suspect sera. Antigen and 
antibody titration was done as follows: rPvAMA-1 was titerat-
ed, using a checkerboard titration in which flat bottom plates 
were coated with 100 μl of rPvAMA-1 serially diluted starting 
from the initial protein concentration of 20 μg/ml in sodium 
carbonate buffer, pH 9.6 (coating buffer) per well and incu-
bated in a humid chamber at 4˚C overnight. The wells were 
washed 3 times with PBS-Tween 20 (PBS-T). 
Test procedure
Antigenicity studies were carried out using human serum 
samples from residents of a malaria-endemic area in south of 
Iran. ELISA was performed using rPvAMA-1 coated onto ELISA 
plates to detect antigen-specific antibodies. Determination of 
anti-PvAMA-1 antibodies was done based on binding of this 
antibody (present in the serum sample) to rPvAMA-1 antigen 
coated on ELISA plates (Nunc, Roskilde, Denmark) and finally 
to evaluate the sensitivity and specificity of the test, ELISA was 
performed on the 168 collected sera as described previously. 
The assay of 60 collected sera was carried out to define cut off 
to separate positive from negative sera in the study po  pulation.
To each previously coated well, known positive and negative 
sera diluted to 1:10, 1:40, 1:80, and 1:160 in PBS-T were add-
ed, respectively. Plates were incubated in a humid chamber at 
room temperature for 1 hr and then were washed with PBS-T 
3 times. To assess the binding of antibody to rPvAMA-1 anti-
gen coated wells, 100 µl of 1:1,000 dilution of polyclonal anti-
human IgG alkaline phosphatase conjugated (DakoCytoma-
tion, Produktionsvej, Denmark) was added to the plates which 
were then incubated for 1 hr in a humid chamber at room tem-
perature and finally washed 3 times with PBS-T. A 100 µl of 
substrate solution PNP (Sigma, St. Louis, Illinois, USA) in Di-
Ethanolamine was added to each well, and the colour permit-
ted to develop at room temperature for 20 min in a dark place. 
The reaction was stopped by adding of 50 µl 3N NaOH. The 
optical density (OD) of the samples was measured at 405 nm 
using a Titerteck (Helsinki, Finland) multiscan ELISA plate rea-
der. All assays were tested in duplicate. Finally, the best concen-
trations of antigen and antibody were determined and the de-
signed ELISA was applied to assess present antibodies in natu-
ral infections.
Statistical analysis
The cut-off value was calculated as the mean+2SD of OD 
value of the healthy group sera living in a malaria endemic area. 
Accordingly, OD values higher than mean+2SD were consid-
ered positive. The sensitivity, specificity, positive predictive val-
ue (PPV), negative predictive value (NPV), and diagnostic effi-
ciency of ELISA compared to microscopy for detection of P. 
vivax infection were calculated with the following formula:
Sensitivity=TP/(TP+FN)×100%, specificity=TN/(TN+FP) 
×100%, positive predictive value (PPV)=TP/(TP+FP)×100%, 
negative predictive value (NPV)=TN/(TN+FN)×100%, Diag-
nostic efficiency=(TN+TP)/Total×100% where TP represents 
the true positive, TN true negative, FN false negative, and FP 
false positive.
The degree of agreement between ELISA and the microscopy 
was determined by calculating kappa (κ) values with 95% con-
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press the agreement beyond change, and a ‘κ’ value of 0.21-
0.60 represents a fair to moderate agreement, 0.60-0.80 repre-
sents a substantial agreement, and  >0.80 represents almost 
perfect agreement [12,13]. A probability value of P<0.05 was 
considered statistically significant.
RESULTS
Cloning and expression of the PvAMA­1 gene 
A 1,300 bp PCR product corresponding to the AMA-1 re-
gion was successfully cloned in pUC19. The subcloning was 
performed in pET32a and confirmed by sequencing (GenBank 
ID: HM535663.1). The rPvAMA-1 expression was detected on 
SDS-PAGE and purified successfully. Fig. 1 shows the SDS-PA-
GE analysis for rPvAMA-1 production. Analysis of the purified 
rPvAMA-1 by SDS-PAGE showed a molecular weight of 50 kDa 
(Fig. 2), and the concentration of the eluted protein was calcu-
lated as 189.2 µg/ml by the Bradford assay. 
Calculation of suitable concentration of antigen and sera 
Based on the results from the checkerboard test, the best con-
centration for antigen was defined as 2.36 µg of rPvAMA-1/ml 
of sodium carbonate buffer, pH 9.6 in each well, and the best 
dilution to detect malaria antibody was determined as 1/80 
dilution. So, in order to attach all specific antibodies to the an-
tigen, all tested sera were diluted at an optimal dilution of 1/80 
and added to the ELISA plates coated with rPvAMA-1. Human 
antibodies against PvAMA-1 were detected by an indirect ELI-
SA. The highest dilution that made an absorbance value over 
the highest absorbance of the negative control was considered 
as the best point titer to assess present antibodies in sera. The 
cut off point for rPvAMA-1 was calculated as OD 0.311.
Assay of clinical sensitivity of ELISA 
As shown in Table 1, ELISA test showed 81.0% clinical sen-
sitivity for patients with proven malaria vivax infection.
Determination of specificity in non­exposed controls 
The results indicated that a total of 15.5% of the 84 subjects 
reacted with rPvAMA-1. The specificity was then determined as 
84.5%. Although the rPvAMA-1 showed reactivity with 3 sam-
ples from P. falciparum sera but no cross reaction was observed 
with other samples collected from other diseases. 







Fig. 1. SDS-PAGE analysis for rPvAMA-1 production. Lane 1: E. 
coli BL21(DE 3) bacterial lysate containing pET 32 a plasmid (ne-
gative control). Lane 2: E. coli BL21(DE 3) bacterial lysate con-
taining pET 32 a-AMA-1 recombinant plasmid. Lane 3: Protein 
size marker.







Fig. 2. SDS-PAGE analysis of rPvAMA-1 expression. PSM: pro-
tein size marker (kDa). PvAMA-1: His tagged recombinant anti-
gen purified by Ni-NTA affinity column after IPTG induction.  Haghi et al.: A recombinant P. vivax AMA­1 to detect human infection   19
Diagnostic value of indirect ELISA 
Table 2 gives determination of the sensitivity, specificity, PPV, 
NPV provided, and the diagnostic efficiency of anti-PvAMA-1 
antibody using indirect ELISA.
DISCUSSION
Vivax malaria is considered as a highly prevalent infection 
with a global geographic distribution. It is extremely a prereq-
uisite to find immunological antigens of malaria parasites caus-
ing natural immune responses to design a suitable diagnostic 
method [14]. However, the difficulty of vivax malaria in vitro 
cultivation to isolate candidate immunodiagnostic antigens, 
makes it difficult to perform. Several recombinant constructs 
obtained from asexual blood-stages of parasites have been rec-
ognized as potential antigenic candidates, and studies on hu-
man sera from patients infected with Plasmodium have shown 
antibody titers to them [15-18]. Studies have also addressed 
the potential use of rPvAMA-1 as a potential malaria antigen 
for diagnosis [19,20]. AMA-1 is a unique protein of Plasmodi-
um that has been well-characterized and its function can be 
blocked by antibodies [21,22]. Moreover, the protein corre-
sponding to the sequence of P. vivax AMA-1 is strongly immu-
nogenic to humans exposed to natural infections [10,23]. The 
rationale of the present study was to identify the human natu-
rally acquired immune responses to rPvAMA-1 representing 
the 3 domains of PvAMA-1 in Iran. In the current work, a re-
combinant plasmid, pET32a-AMA-1, was constructed and the 
related protein was used as a coated antigen in ELISA plates. 
Our results provided a suitable expression vector with a poten-
tial power to express the AMA gene in prokaryotic cells, and 
therefore, it will be easily accessible to prepare related recom-
binant protein in large amount in the future. This product could 
be used to investigate about vaccination as well as to establish 
a diagnostic method to conduct epidemiological studies.
Recognition of the rPvAMA-1 was then assessed by detection 
of circulating natural antibodies using P. vivax-infected sera col-
lected from endemic regions in Iran. A total of 81.0% of the 
individuals showed antibodies to this recombinant antigen, 
showing relatively high frequency of reacting sera from indi-
viduals with patent P. vivax infection to rPvAMA-1 antigen. Se-
rum antibody responses to rPvAMA-1 in different areas of Bra-
zil, Sri Lanka, and Korea [10,23,24] have been reported. In a 
study from Brazil [10], antibody assay using ELISA test has de-
monstrated 85.0% (for IgG) and 48.5% (for IgM) sensitivity, 
respectively. The test was based on an antibody assay against 
rPvAMA-1 corresponding 3 domains of PvAMA-1in individu-
als infected with P. vivax malaria. Kim et al. [24] showed that 
the ELISA test based on multiple proteins of blood stages has 
resulted in 80.3% sensitivity with serum samples. While only 
46.1% of sera reacted with rPvAMA-1, Wickramarachchi et al. 
[23] reported that cytophilic antibodies against 3 domains of 
PvAMA-1 were more obvious when residents in endemic areas 
stayed more exposures to infection. There is no previous report 
on anti-PvAMA-1 antibodies in Iran, but Mehrizi et al. [25] des-
cribed higher immune responses of PvMSP-1. The antibodies 
to PvMSP-1 were detected in 86.1% in serum samples from 
patient with patent P.vivax infection.
However, rPvAMA-1 could be applied as an immunodomi-
nant antigen for the diagnosis vivax malaria. In a separate as-
sessment, the results of ELISA were compared with those of 
IFA. The frequencies of individuals who responded to a recom-
binant protein derived from PvAMA-1in ELISA were signifi-
cantly higher than the frequency of responders to IFAT using a 
conventional intact whole parasite antigen. The percentage of 
P. vivax samples which reacted with IFA was 36%, while ELISA 
antibody test showed more than 2 times highly sensitive as 
IFA test.
In our study, the rPvAMA-1 reacted with 3 samples from P. 
falciparum. This seemingly cross-reactivity can be explained ei-
ther by possible previous infection with P. vivax because of the 
residential situation of the residents in the endemic areas, or 
by dominancy of P. falciparum AMA-1 according to previous 
reports explaining that PfAMA-1 is highly immunogenic for 
the most individuals who exposed to P. falciparum infection 
Table 1. Comparison between ELISA using recombinant protein 
PvAMA-1 (cut-off=0.311) and microscopy results
ELISA
a+  ELISA- Total
No. (%) No. (%) No. (%)
Microscopy (positive)  68 (81.0) 16 (19.1) 84 (100.0)
Microscopy (negative) 13 (15.5) 71 (84.5) 84 (100.0)
Total 81 (48.2) 87 (51.8) 168 (100.0)
aELISA had a clinical sensitivity of 81.0% and a clinical specificity of 84.5% 
for P. vivax.
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against P. vivax [26]. In either explanation, this implies that 
AMA-1 is an extremely immunogenic molecule during natural 
Plasmodium infection.
There exists an old report done by Eddrissian and others in 
1979 in Iran, who employed an ELISA test to detect infections 
in human sera. As they reported, natural antibodies were de-
tected with Aotus monkey-derived P. falciparum and P. fieldi mal-
aria antigens for ELISA. Anti-malaria antibodies were detected 
in titers ≥1/40 in 24.3% and 34.9% residents from villages in 
Bandar Abbas and Minab areas of southern Iran, respectively. 
They also reported that IFA showed higher positivity rate than 
ELISA. 
The presence of antibodies in sera from humans infected 
with P. vivax that recognized the recombinant protein related 
to the partial region of PvAMA-1 indicated that the expression 
systems successfully rebuilt domains conformation relating to 
cysteine residues and epitopes resembling the native PvAMA-1 
that induce natural immunity in patients. These residues re-
mained as the natural protein expressed in blood stage form 
of parasites [27,28]. It is accordingly suggested that multiple 
proteins should be constructed and used to evaluate humoral 
immunity in cases of vivax malaria, because the complexity of 
immunity occurs in patients and the sensitivity of a multiple 
antigens are considered more convincing [29].
Our results showed that there is reasonable agreement in the 
results between microscopy, as a standard method, and ELISA 
using rPvAMA-1 for detection of P. vivax infection.
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